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ABSTRACT		
Background:	Heavy	menstrual	bleeding	(HMB)	is	a	common,	chronic	problem	burdening	women	and	
health	services.	However	long-term	evidence	on	treatment	in	primary	care	is	lacking.		
Aim:	To	assess	the	effectiveness	of	commencing	levonorgestrel	intra-uterine	system	(LNG-IUS)	or	
usual	medical	treatments	for	women	presenting	with	HMB	in	general	practice.	
Design:	Pragmatic,	multicentre,	parallel,	open-label	randomised	controlled	trial	
Setting:	63	primary	care	practices	
Methods:	571	women,	aged	25-50,	with	HMB	were	randomised	to	LNG-IUS	or	usual	medical	
treatment	(tranexamic/mefenamic	acid,	combined	oestrogen-progestogen,	or	progesterone	alone).	
The	primary	outcome	was	the	patient	reported	Menorrhagia	Multi-Attribute	Scale	(MMAS,	
measuring	effect	of	HMB	on	practical	difficulties,	social	life,	psychological	and	physical	health,	work	
and	family	life;	scores	from	0	-100).	Secondary	outcomes	included	surgical	intervention	(endometrial	
ablation/hysterectomy),	general	quality-of-life,	sexual-activity	and	safety.	
Results:	At	five	years	post-randomisation	424	(74%)	women	provided	data.	While	the	difference	
between	LNG-IUS	and	usual-treatment	groups	was	not	significant	(3.9	points;	95%	CI:	-0.6	to	8.3;	
p=0.09),	MMAS	scores	improved	significantly	in	both	groups	from	baseline	(mean	increase,	44.9	and	
43.4	points,	respectively;	p<0.001	for	both	comparisons).	Rates	of	surgical	intervention	were	low	in	
both	groups	(surgery-free	survival	was	80%	and	77%;	HR:	0.90;	95%CI:	0.62	to	1.31;	p=0.6).	There	
was	no	difference	in	generic	quality	of	life,	sexual-activity	scores	or	serious	adverse	events.		
Conclusion:	Large	improvements	in	symptom	relief	across	both	groups	show	treatment	for	heavy	
menstrual	bleeding	can	be	successfully	initiated	in	primary	care	with	long-term	benefit	for	women,	
and	with	only	modest	need	for	surgery.	
	
Trial	Registration:	International	Clinical	Trial	Registry	Number:	86566246	
Introduction	
Heavy	menstrual	bleeding	(HMB)	is	a	common	and	debilitating	problem	that	can	significantly	affect	
women’s	lives.			With	an	annual	community	incidence	of	25%	among	women	aged	18-54,	1	one	
million	women	seek	help	for	this	problem	each	year	in	the	UK2,	mostly	in	general	practice,3	and	it	
accounts	for	12%	of	all	gynaecology	referrals.4	Despite	the	many	factors	influencing	women’s	
decisions	not	to	seek	help,5	the	cost	of	health	care	for	HMB	is	substantial.		In	a	recent	national	audit	
of	care	of	HMB	in	England	and	Wales,	almost	a	third	of	women	had	received	no	previous	medical	
treatment	before	referral	to	secondary	care,	with	over	40%	of	women	having	surgical	intervention	in	
the	year	following	first	attendance	at	hospital.6			
	
The	National	Institute	of	Clinical	and	Healthcare	Excellence	(NICE)	defines	heavy	menstrual	bleeding	
as	that	which	interferes	with	a	woman’s	physical,	emotional,	social	and	material	quality	of	life,	and	
which	can	occur	alone	or	with	other	symptoms.2	This	recognises	women’s	perceptions	of	heavy	
menstrual	bleeding	and	what	they	find	troublesome	does	not	correlate	well	with	a	traditional	
biomedical	focus	on	volume	of	blood	loss.7	For	clinical	practice,	HMB	should	be	regarded	as	more	
subjectively	defined	by	women,	focusing	on	perceived	impact	on	their	lives	rather	than	menstrual	
blood	loss	in	itself	2,	8;	in	addition	to	physical	and	psychological	health,	this	includes	interference	with	
social,	working	and	family	life	or	practical	burden	of	sanitary	care.9		
	
At	the	commencement	of	the	current	trial,	guidelines	for	HMB	recommended	initial	management	
should	usually	be	medical,	using	either	oral	tranexamic	acid	or	mefenamic	acid;	or	using	the	
combined	oral	contraceptive	(COC),	or	the	levonorgestrel-releasing	intrauterine	system	(LNG-IUS)	for	
women	requiring	contraception,	or	for	those	not	requiring	contraception	but	prepared	to	accept	
hormonal	treatments.10		In	2007,	similar	guidelines	from	NICE	recommended	this	range	of	
pharmaceutical	treatments,	and	underlined	the	potential	for	more	women	with	HMB	to	be	managed	
by	their	general	practitioners	(GPs),	avoiding	secondary	care.2		
Five	trials	in	gynaecological	settings	(involving	44-165	women,	and	3-12	months	follow	up)	have	
found	LNG-IUS	more	beneficial	in	reducing	menstrual	blood	loss	than	treatments	such	as	mefenamic	
acid	or	COC.11	However	evidence	on	how	helpful	treatments	are	in	improving	women’s	quality	of	life,	
or	their	use	in	primary	care,	is	lacking.	11	Our	earlier	findings	from	the	current	trial	found	both	LNG-
IUS	and	usual	medical	treatments	significantly	reduced	the	effect	of	HMB	on	women’s	quality	of	life	
in	the	first	two	years	of	treatment,	but	LNG-IUS	was	the	more	effective.12	However	HMB	may	be	
chronic	and	episodic	over	several	years.13	A	recent	Cochrane	review	recommended	trials	of	at	least	
five	years	are	needed,	which	should	include	a	focus	on	women’s	quality	of	life.11		
	
Women’s	and	their	GPs’	decisions	about	medical	treatments	for	HMB	also	include	wider	dynamic	
considerations	such	as	women’s	attitudes	to	using	oral	treatment	or	having	an	intrauterine	device,	
changing	plans	about	wanting	to	conceive	or	need	for	contraception,	or	anticipating	surgical	
intervention.		Thus,	long-term	evidence	is	needed	to	help	guide	decision-making	in	practice.		
In	this	pragmatic	randomised	controlled	trial,	we	assessed	outcomes	at	five	years	of	commencing	
LNG-IUS	or	usual	medical	treatments	for	women	presenting	with	HMB	in	primary	care.			
	
	
	
	
Methods	
Population	
Women	between	25	and	50	years	of	age	who	presented	to	their	GP,	affected	with	HMB	involving	at	
least	three	consecutive	menstrual	cycles,	were	eligible	to	participate.	Women	were	excluded	if	they	
intended	to	become	pregnant	over	the	next	5	years,	were	taking	hormone-replacement	therapy	or	
tamoxifen,	had	intermenstrual	bleeding	(between	expected	periods),	postcoital	bleeding	or	findings	
suggestive	of	fibroids	(abdominally	palpable	uterus	equivalent	in	size	to	that	at	10	to	12	weeks’	
gestation)	or	other	disorders,	or	had	contraindications	to	or	a	preference	for	either	the	
levonorgestrel-	IUS	or	usual	medical	treatments.	Women	with	heavy,	irregular	bleeding	were	
ineligible	unless	the	results	of	endometrial	biopsy	were	reported	to	be	normal;	no	further	
investigations	were	mandated	by	the	protocol.	All	patients	provided	written	informed	consent.	
Randomization	
Patients	were	assigned	to	a	study	group	by	telephone	or	a	Web-based	central	randomization	service	
at	the	University	of	Birmingham	Clinical	Trials	Unit.	A	computerized,	minimized	randomization	
procedure	was	used	to	achieve	balance	between	the	groups	with	respect	to	age	(<35	years	or	≥35	
years),	body-mass	index	(BMI;	the	weight	in	kilograms	divided	by	the	square	of	the	height	in	metres)	
(≤25	or	>25),	duration	of	symptoms	(<1	year	or	≥1	year),	need	for	contraception	(yes	or	no),	and	
HMB	alone	or	HMB	accompanied	by	menstrual	pain.		
Study	interventions	and	compliance	
Eligible	women	who	provided	written	informed	consent	were	randomly	assigned	to	either	LNG-IUS	
or	usual	medical	treatment.	Usual	treatment	options	included	oral	tranexamic	acid,	mefenamic	acid,	
norethisterone,	a	combined	oestrogen–progestogen	or	progesterone-only	oral	contraceptive	pill	
(any	formulation);	or	medroxyprogesterone	acetate	injection	and	were	chosen	by	the	clinician	and	
patient	on	the	basis	of	any	contraceptive	needs	or	the	desire	to	avoid	hormonal	treatment.2,14	The	
particular	medical	treatment	to	be	used	was	specified	before	randomization.	Subsequently,	and	in	
line	with	real	life	practice,	treatments	could	be	changed	(from	one	medical	treatment	to	another,	
from	the	LNG-IUS	to	a	usual	medical	treatment,	or	from	a	usual	medical	treatment	to	the	LNG-IUS),	
or	could	be	discontinued	because	of	a	perceived	lack	of	benefit,	side	effects,	a	change	in	the	need	for	
contraception,	referral	for	endometrial	ablation	or	hysterectomy,	or	any	other	reasons	according	to	
usual	clinical	practice.2,14	Treatment	changes	reported	by	women	were	confirmed	with	their	GP.	
Outcome	measures	and	follow-up	
The	primary	outcome	measure	was	the	patient	reported,	condition-specific	Menorrhagia	Multi-
Attribute	Scale	(MMAS)	at	five	years	follow-up.15,16	The	MMAS	is	designed	to	measure	the	effect	of	
heavy	menstrual	bleeding	on	six	domains	of	daily	life.	Possible	responses	are:		not	affected/slightly	
affected/moderately	affected/severely	affected	for	each	domain.	The	scores	for	each	domain	are	
weighted	according	to	the	perceived	importance	of	that	domain	to	women	with	this	condition.		In	
order	of	importance,	from	highest	to	lowest,	the	domains	are:	family	life	and	relationships;	physical	
health;		work	and	daily	routine;		practical	difficulties;	psychological	health;		social	life.	Summary	
scores,	which	range	from	zero	(severely	affected)	to	100	(not	affected),	were	assessed.	The	MMAS	
has	a	high	degree	of	reliability	and	internal	consistency,15	has	good	content	and	construct	validity,17,18	
is	responsive19,20	and	is	acceptable	to	respondents.	15,16,19,20		
Secondary	outcome	measures	included	general	health-related	quality	of	life	and	sexual	activity.	To	
assess	generic	quality	of	life,	we	used	three	instruments:	the	Medical	Outcomes	Study	36-Item	Short-
Form	Health	Survey	(SF-36),	version	2	(with	scores	ranging	from	zero	[severely	affected]	to	100	[not	
affected]);	the	EuroQoL	Group	5-Dimension	Self-	Report	Questionnaire	(EQ-5D)	descriptive	system	
(with	scores	ranging	from	−0.59	[health	state	worse	than	death]	to	100	[perfect	health	state]);	and	
the	EQ-5D	visual-analogue	scale	(with	scores	ranging	from	zero	[worst	health	state	imaginable]	to	
100	[most	perfect	health	state	imaginable]).	The	validated	Sexual	Activity	Questionnaire	measures	
pleasure	(with	scores	ranging	from	zero	[lowest	level]	to	18	[highest	level]),	discomfort	(with	scores	
ranging	from	zero	[greatest]	to	6	[none]),	and	frequency	(assessed	relative	to	perceived	usual	activity	
as	an	ordinal	response).21	Responses	for	all	outcomes	were	obtained	before	randomization	and	by	
mail	at	five	years	after	randomization.	Data	were	collected	from	participating	GPs	regarding	all	
serious	adverse	events,	defined	as	adverse	events	that	resulted	in	death,	disability,	or	hospitalization.	
Patients	were	also	asked	to	report	any	hospitalizations	and	adverse	events	leading	to	discontinuation	
of	the	study	treatments.		
Study	oversight	
Study	oversight	was	provided	by	an	independent	steering	committee	and	an	independent	data	and	
safety	monitoring	committee,	whose	three	reviews	of	interim	data	provided	no	reason	to	modify	the	
trial	protocol	on	the	basis	of	pragmatic	stopping	criteria.22	The	study	was	conducted	in	accordance	
with	the	protocol,	available	at	http://www.nets.nihr.ac.uk/projects/hta/020602.	Approval	of	the	
study	was	obtained	from	the	South-West	England	Multicentre	Research	Ethics	Committee,	and	
clinical	trial	authorization	was	received	from	the	Medicines	and	Healthcare	Products	Regulatory	
Authority.	All	medications	and	devices	were	prescribed	by	providers	through	the	National	Health	
Service.	The	manufacturers	of	any	therapeutic	agents	used	in	the	study	were	not	involved	in	any	
aspect	of	the	trial.		
Statistical	considerations	
The	study	was	designed	to	have	90%	power	(at	p<0.05)	to	detect	a	small-to-moderate	difference23	-	
0.3	of	a	standard	deviation	-	in	the	primary	outcome.	This	required	responses	from	470	patients;	we	
increased	the	sample	size	to	570	to	allow	for	up	to	20%	loss	to	follow-up.	At	five	years	follow	up	we	
received	424	responses;	a	post-hoc	calculation	suggested	this	total	would	provide	87%	power	
(p=0.05)	to	detect	the	same	size	of	difference.		For	progression	to	surgical	intervention	
(hysterectomy	or	endometrial	ablation),	using	an	assumed	rate	of	35%	in	the	standard	arm	(a	figure	
that	was	set	out	in	the	protocol),	424	women	would	provide	80%	power	(p=0.05)	to	detect	an	
absolute	reduction	of	12%,	i.e.	35%	down	to	23%.	
Analyses	were	performed	according	to	the	intention-to-treat	principle.	Differences	between	groups	
at	five	years	were	examined	by	analysis	of	covariance	(adjusting	for	baseline	score).	Changes	
between	baseline	score	within	groups	were	examined	using	paired	t-tests.	The	primary	analysis	was	
based	on	the	fact	that	some	patients	declined	to	complete	the	MMAS,	indicating	on	the	form	that	
they	were	no	longer	bleeding	and	the	questions	did	not	appear	relevant	to	them.	Thus,	these	
patients	were	assigned	the	best	possible	score	(100).	This	assumption	was	further	tested	through	
sensitivity	analyses	by	making	no	assumption	about	those	questionnaires	that	were	returned	blank,	
i.e.	MMAS	scores	were	assumed	to	be	missing.		
Kaplan-Meyer	plots	were	constructed	for	a	time	to	surgery	and	a	time	to	treatment	change	analysis,	
with	women	censored	at	date	to	last	follow-up	or,	if	appropriate,	date	to	death,	withdrawal	or	loss	to	
follow-up.	A	Cox	proportional	hazards	model	was	used	to	construct	hazard	ratios.	Surgery-free	
analysis	was	then	re-performed,	excluding	participants	who	crossed	over	from	one	treatment	group	
to	another.	All	the	effect	sizes	are	presented	with	95%	confidence	intervals	and	p-values.	All	tests	
and	corresponding	p-values	were	two-sided.	The	statistical	package	SAS	9.2	was	used	for	all	the	
statistical	analysis.	
Results	
Patients	and	follow-up	
Between	February	2005	and	July	2009,	a	total	of	571	women	with	heavy	menstrual	bleeding	from	63	
primary	care	centres	were	randomly	assigned	to	either	the	LNG-IUS	(285	women)	or	usual	medical	
treatment	(286	women).	Baseline	characteristics	were	similar	between	the	two	treatment	groups	
(Table	1).	For	215	(75%)	of	the	women	assigned	to	usual	medical	treatment,	the	initial	prescription	
was	for	mefenamic	acid,	tranexamic	acid,	or	a	combination	of	the	two	drugs;	55	(19%)	of	the	women	
in	the	usual-treatment	group	required	contraception.	
Study-questionnaire	booklets	were	returned	by	424	(74%)	of	participants	at	five	years	(Fig.	1).	One	
hundred	and	fifteen	women	(27%)	indicated	they	were	no	longer	having	periods	and	so	did	not	
complete	the	MMAS	section.	These	women	completed	other	sections	of	the	questionnaire	and	still	
contributed	to	the	analysis	of	MMAS	responses	(see	statistical	considerations).	
The	proportion	of	patients	still	taking	their	allocated	treatment	at	five	years	was	47%	(95%CI:	40%	to	
52%)	in	the	LNG-IUS	group	and	15%	(95%CI:	11%	to	20%)	in	the	usual-treatment	group	(Fig.	2).	Of	the	
228	recorded	instances	of	treatment	change	in	women	allocated	usual	medical	treatment,	97	(43%)	
were	to	LNG-IUS.	In	the	LNG-IUS	group,	57/148	(39%)	treatment	switches	were	to	usual-treatment.	
Reported	reasons	for	discontinuation	of	treatment	were	varied,	with	lack	of	treatment	efficacy	most	
commonly	cited	(24%	[36/148]	in	the	LNG-IUS	group	and	41%	[94/228]	in	the	usual-treatment	group.	
Further	details	are	summarised	in	Tables	1.1	and	1.2	of	the	appendix.		
	
Primary	outcome	-	MMAS	
Women	started	out	with	average	scores	approximately	40	points	out	of	100	on	the	MMAS,	indicating	
they	were	substantially	affected	by	HMB	at	presentation	to	their	GP.	At	five	years,	these	scores	were	
significantly	improved	to	over	80	points	out	of	100	in	both	groups	(Table	2).	This	improvement	was	
higher	on	average	among	women	assigned	to	LNG-IUS	but	the	difference	was	not	statistically	
significant	(3.9	points;	95%	confidence	interval	[CI],	-0.6	to	8.3;	p=0.09).	The	same	analysis	without	
any	assumption	about	MMAS	scores,	where	the	form	was	returned	blank	and		the	woman	indicated	
she	was	no	longer	bleeding,	returned	a	similar	result	(5.2	points	difference	in	favour	of	LNG-IUS;	95%	
confidence	interval	[CI],	-0.4	to	10.8;	p=0.07).		
	
Surgical	interventions		
Fifty-three	events	(endometrial	ablation	or	hysterectomy)	in	the	LNG-IUS	group	versus	56	in	the	
usual-treatment	group	were	included	in	the	surgery-free	survival	analysis	(109	events	in	total).	This	
difference	was	not	statistically	significant	(HR:	0.90;	95%CI:	0.62	to	1.31;	p=0.6)	(Fig.	3).	Analysis	
excluding	participants	who	crossed	over	from	one	group	to	another	returned	a	similar	result	(HR:	
0.96;	95%CI:	0.60	to	1.52;	p=0.9).	Five-year	surgery-free	survival	rates	were	80%	(95%CI:	74%	to	84%)	
in	the	LNG-IUS	group	versus	77%	(95%CI:	71%	to	82%)	in	the	usual-treatment	group.	In	total,	there	
were	115	surgical	interventions:	24	ablations	in	the	LNG-IUS	group	versus	31	in	the	usual-treatment	
group	and	30	hysterectomies	in	both	groups	(six	more	events	than	quoted	above	as	six	patients	had	
both	types	of	surgery).	
	
Generic	quality	of	life	and	sexual	activity	
Responses	to	the	Euroqol	and	SF-36	instruments	were	generally	significantly	improved	from	baseline	
in	both	groups	(Table	3);	the	only	statistically	significant	difference	between	groups	was	seen	in	the	
general	health	perception	domain	of	the	SF-36	and	favoured	LNG-IUS	(4.7	points,	95%CI:	0.6	points	
to	8.8	points;	p=0.02).	The	treatment	groups	did	not	differ	significantly	with	respect	to	any	of	the	
domains	of	the	Sexual	Activity	Questionnaire.		
Safety	
There	was	no	significant	difference	between	the	groups	in	the	total	number	of	serious	adverse	
events	(p=0.32).	These	are	listed	in	Table	2	of	the	appendix.	
Discussion	
This	pragmatic	trial	shows	women	affected	by	heavy	menstrual	bleeding	can	be	effectively	helped	in	
primary	care	by	initiating	LNG-IUS	or	usual	medical	treatment,	with	long-term	benefit,	and	only	
modest	need	for	surgery.	Women	in	either	treatment	group	experienced	similar	and	significant	
improvement	in	condition-specific	quality	of	life	after	five	years.	Women	receiving	usual	medical	
treatment	were	no	more	likely	to	need	surgical	intervention	than	those	treated	with	insertion	of	an	
LNG-IUS,	with	rates	of	surgical	intervention	(endometrial	ablation,	hysterectomy)	remaining	low	in	
both	groups	(approximately	20%).	Generic	quality	of	life	scores	were	similarly	improved	in	both	
groups	and	there	was	no	difference	in	sexual-activity	scores	or	serious	adverse	events.	
Strengths	and	weaknesses		
This	is	the	largest	randomised	trial	available	of	medical	treatments	for	HMB.	Generalisability	is	
strengthened	by	a	pragmatic,	multicentre	design,	mimicking	treatment	decisions	in	‘real	life’	primary	
care,	involving	a	large	sample	ethnically	representative	of	the	UK	population.	Outcomes	have	been	
assessed	in	the	longer	term,	appropriate	to	the	chronic	nature	of	HMB.	We	used	a	validated	patient-
centred	primary	outcome	reflecting	women’s	assessments	of	the	impact	of	HMB	on	their	quality	of	
life,	in	line	with	guidance	for	assessing	HMB,2	rather	than	a	biomedical	focus	on	menstrual	blood	loss	
itself.		While	use	of	indirect	measures	of	menstrual	blood	loss	were	considered,	pictorial	blood	
assessment	charts	correlate	poorly	with	blood	loss	and	are	not	consistently	accurate.8		
Given	five	years	since	study	entry,	a	relatively	high	follow	up	has	been	sustained	to	include	424	of	
571	(74%)	women	randomised.		The	range	of	drugs	within	the	usual	medical	treatment	group	
includes	those	used	in	routine	practice,	but	we	acknowledge	this	limits	ability	to	compare	any	
individually	with	the	LNG-IUS.	The	intention-to-treat	analysis	may	be	considered	overly	conservative	
by	some	–	particularly	given	the	long	follow-up	period	-	but	alternatives	such	as	per	protocol	
analyses	are	likely	to	exaggerate	treatment	effects	as	they	restrict	analyses	to	only	those	patients	
happy	with	treatment	performance.24	While	there	was	no	statistically	significant	difference	in	
primary	outcome	between	the	two	groups,	we	note	significant	proportions	of	women	reported	their	
periods	had	ceased,	or	had	changed	or	ceased	treatments,	and	this	may	have	limited	the	ability	to	
detect	a	difference.	However	such	changes	might	be	expected	in	real	life	over	five	years	and	are	
consistent	with	experience	from	national	audit	of	care	for	HMB.6		
Relation	to	other	studies	
A	2015	Cochrane	review	highlights	lack	of	research	on	medical	management	of	HMB	in	primary	care,	
the	need	for	evidence	on	HMB	related	quality	of	life	outcomes,	and	for	data	from	longer	term	trials	
reporting	beyond	two	years.11	The	current	trial	contributes	new	evidence	to	these	three	gaps.	We	are	
not	aware	of	similar	long	term	comparisons	of	medical	treatments	initiated	in	primary	care.	In	
secondary	care,	trials	of	similar	length	have	compared	LNG-IUS	to	hysterectomy25	rather	than	other	
medical	treatments,	or	endometrial	resection	to	oral	medication.26		
	
Our	results	are	encouraging	in	showing	both	HMB-specific	and	generic	quality	of	life	for	women	were	
significantly	improved	five	years	after	commencing	either	usual	medical	treatment	or	LNG-IUS.	The	
size	of	improvement	–	approximately	equivalent	to	two	standard	deviations	-	is	likely	to	be	a	very	
large	effect.23	Women	were	considerably	affected	by	HMB	at	presentation	to	their	GP,	and	
improvement	in	MMAS	score	from	baseline	(by	43.9	and	44.9	points	for	usual	medical	treatment	or	
for	LNG-IUS	respectively)	reflects	a	clinical	change	of	at	least	one	category	in	all	six	MMAS	domains:	
(practical	difficulties,	social	life,	psychological	health,	physical	health,	work	and	daily	routine,	and	
family	life	and	relationships),	from	being	substantially	to	minimally	affected	by	HMB,	for	example,	
from	frequent	to	occasional	disruptions	of	work	and	daily	routine.	
	
The	greater	clinical	efficacy	of	LNG-IUS	compared	to	usual	medical	treatments	seen	at	two	years	in	
this	trial	12	has	now	diminished.	At	five	years,	only	a	borderline	difference	(p=0.09)	in	favour	of	LNG-
IUS	has	been	observed.	This	was	estimated	to	be	3.9	points	on	average	which	is	less	than	one-fifth	of	
a	standard	deviation	and	unlikely	to	be	clinically	meaningful.	We	note	this	may	be	unsurprising	given	
the	high	proportions	of	women	who,	by	five	years	after	treatment	allocation,	had	either	changed	to	a	
treatment	that	worked	for	them,	or	had	ceased	bleeding	either	naturally	or	through	surgical	
intervention.	Retention	rates	at	five	years	were	15%	with	usual	medical	treatment	and	47%	in	the	
LNG-IUS	group.	This	may	reflect	greater	impact	on	symptoms	of	LNG-IUS.	Another	factor	may	be	that	
women	could	more	easily	choose	to	stop	usual	medical	treatment	when	desired	or	according	to	their	
symptoms,	without	need	for	consultation	and	removal	of	their	intra-uterine	device.																																																
	
Similar	reasons	may	explain	our	data	providing	no	evidence	of	any	reduction	in	surgical	interventions	
with	LNG-IUS	compared	to	usual	medical	therapy,	even	when	we	discounted	treatment	cross-overs.	
At	two	years	post-randomisation,	surgical	interventions	were	low	at	about	10%	in	both	medical	
treatment	groups12	and	this	has	approximately	doubled	to	20%	in	both	groups	at	five	years.	This	is	
still	much	lower	than	the	58%	surgical	intervention	rate	at	two	years	identified	in	an	earlier	Cochrane	
review	of	trials	comparing	oral	medical	therapy	to	surgical	interventions	for	HMB,	though	these	were	
in	secondary	care	settings.27	The	relatively	low	surgical	intervention	rates	in	the	current	trial	may	also	
possibly	be	explained	by	the	exclusion	of	women	with	enlarged	uteri	or	known	disease	such	as	
fibroids	that	were	deemed	unsuitable	for	treatment	in	a	community	setting.			
	
Implications	for	clinical	practice	
Our	data	have	been	obtained	in	the	context	of	real	life	clinical	practice,	for	a	chronic	and	episodic	
problem,	where,	as	experienced	in	this	trial,	women	may	commonly	discontinue	or	change	
treatments	for	their	HMB.6	The	inclusion	criteria	also	underline	that	women	who	do	not	have	a	
uterus	palpable	abdominally,	or	who	have	had	normal	investigation	for	irregular	periods,	can	be	
successfully	treated	in	primary	care.	
	
The	results	provide	valuable	practical	information	for	women	and	GPs	when	weighing	up	choice	of,	
and	what	to	expect	in	the	longer	term	from	treatments	for	HMB.	This	needs	to	take	account	of	
individual	women’s	differing	preferences	for	oral	treatments	or	insertion	of	an	intra-uterine	device	
left	in	situ	and	changing	needs	for	contraception	or	fertility.28.	The	study	shows	women	can	benefit	
significantly	from	choosing	either	usual	medical	or	LNG-IUS	treatment.		Just	under	half	of	women	
might	be	expected	to	retain	their	LNG-IUS	at	five	years,	while	most	women	have	ceased	usual	oral	
treatments	by	this	stage.	Women	able	to	choose	LNG-IUS,	if	suited	to	their	circumstances,	may	
experience	less	discontinuation	of	treatment,	and	a	better	effect	at	two	years	12.	However	it	will	not	
suit	all	women	-	36%	in	the	current	trial	had	had	their	LNG-IUS	removed	by	two	years	because	of	
persisting	HMB	or	unpredictability	of	bleeding	12	and	this	is	a	well-recognised	problem	29.		
The	low	rates	of	progression	to	surgical	intervention	observed,	five	years	from	initial	presentation	
with	HMB	to	their	GP,	emphasise	the	feasibility	and	importance	of	treating	women	with	HMB	in	
primary	care.	Avoiding	referrals	to	secondary	care	may	reduce	high	operative	intervention	rates.	6,	30	
Wider	public	awareness	is	needed	to	encourage	women	to	seek	help	for	HMB	as	they	are	likely	to	
benefit	from	LNG-IUS	or	usual	medical	treatment	in	primary	care.	Commensurate	availability	of	
expertise	to	offer	this	range	of	medical	treatments	should	be	ensured.	While	our	data	suggest	the	
earlier	superiority	of	LNG-IUS	over	the	first	two	years	was	not	sustained	at	five	years,	further	
research	to	confirm	this	by	assessing	women’s	satisfaction	with	and	the	acceptability	of	treatments	
would	be	helpful.	Longitudinal	qualitative	research	is	needed	to	explore	and	understand	women’s	
decisions	in	choosing	treatments	for	HMB	and	experiences	of	using	them	over	the	time.		We	intend	
to	follow	up	patients	to	ten	years	when	we	expect	that	around	half	of	our	cohort	will	have	reached	
the	menopause	to	assess	further	patterns	of	treatment	use,	and	surgical	intervention	rates.		
	
This	pragmatic	trial	confirms	women	affected	by	HMB,	with	no	significant	clinical	risk	factors	on	
history	or	examination,	can	be	safely	helped	by	initiating	medical	treatments	in	primary	care,	with	
long	term	benefit	in	reducing	the	effects	of	HMB	on	their	quality	of	life.		
	
	
How	this	fits	in		
Heavy	menstrual	 bleeding	 is	 a	 chronic	 debilitating	 problem,	 and	 common	 cause	 of	 gynaecological	
referral	and	surgery.	We	lack	evidence	about	 long-term	effectiveness	of	treatment	 in	primary	care.	
This	trial	shows	women	affected	by	this	problem,	with	no	significant	clinical	risk	factors	on	history	or	
examination,	 can	 be	 safely	 helped	 by	 starting	 either	 usual	 medical	 treatments	 or	 levonorgestrel	
intrauterine	 system	 in	 general	 practice.	 These	 treatments	 reduce	 the	 effects	 of	 heavy	 menstrual	
bleeding	on	women’s	lives	over	a	five-year	time	course,	with	most	avoiding	surgical	intervention.		
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